Understand the source comparison
Best Peptides for Chemotherapy Recovery: Clinical Comparison
Before selecting peptides, understand the distinct recovery phases they target and the evidence quality supporting each. Thymalin Thymic epithelial stimulation → T-cell maturation Immune reconstitution (weeks 4–12 post-chemo) Phase II human trials in oncology
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting peptides, understand the distinct recovery phases they target and the evidence quality supporting each.
- Thymalin
- Thymic epithelial stimulation → T-cell maturation
- Immune reconstitution (weeks 4–12 post-chemo)
- Phase II human trials in oncology patients
- 10mg SC 2×/week for 8 weeks
- Strongest evidence for lymphocyte recovery; addresses root cause (thymic involution) rather than symptoms
- BPC-157
- VEGF upregulation + epithelial cytoprotection
- GI mucositis and barrier repair (days 7–30)
- Preclinical models + case reports
- 250–500mcg SC daily for 4–6 weeks
- Compelling mechanistic data; human trials limited to case series; safety profile excellent
- TB-500
- Actin upregulation → stem cell migration
- Tissue regeneration across organs (weeks 2–8)
- Preclinical + veterinary literature
- 2–5mg SC 2×/week for 6 weeks
- Broad regenerative effect; less organ-specific than BPC-157; well-tolerated
- Cerebrolysin
- Neurotrophic factor signaling → synaptogenesis
- Cognitive recovery from neurotoxic agents (weeks 8–24)
- Meta-analysis of cognitive impairment trials (non-cancer populations)
- 10–30mL IV 5×/week for 4 weeks
- Proven cognitive benefit in stroke/dementia; extrapolation to chemo brain reasonable but unstudied directly
- KPV
- NF-κB inhibition → cytokine modulation
- Systemic inflammation resolution (ongoing throughout recovery)
- Preclinical models of colitis and sepsis
- 500mcg–2mg SC daily or oral
- Strong anti-inflammatory mechanism; human dosing protocols still emerging